Publication | Open Access

Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer

Radiation OncologyCancer ImmunosurveillanceNasal SubmucosaMedicineImmunologyNasopharyngeal CancerHead And Neck CancerImmunotherapeuticsHead And Neck Squamous Cell CarcinomaDermatologyRecurrent HeadImmunotherapyOncologyCancer TherapeuticsNeck OncologyCancer ResearchCells AdministrationHealth Sciences